Want to see WGRX full AI Analyst Report?
Top Page
Wellgistics Health Inc
(NASDAQ:WGRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▲(2042.86% Upside)
Action:Reiterated
Date:07/22/26
The score is primarily weighed down by very weak financial performance (steep revenue decline, deeply negative margins, negative equity, and ongoing cash burn). Technicals also point to a weak trend with negative momentum. Corporate events provide some partial offsets (financing and bid-price compliance), but continued equity-compliance and debt stress keep overall risk elevated, while valuation metrics offer limited support due to losses and no indicated dividend.
Positive Factors
Rebranding to DataMeds AI and strategic pivot
The rebrand and stated strategy signal a structural shift toward vertically integrated AI and blockchain healthcare data services. By expanding EinsteinRx and PharmacyChain and targeting patient-controlled data, the company aims to build long-term data assets and platform stickiness that can create recurring revenue and differentiation if execution follows plan.
Negative Factors
Severe profitability deterioration and cash burn
Deeply negative gross and net margins indicate core unit economics are currently unviable: the company is losing money at the operational level and burning cash. Persistent negative operating cash flow requires repeated external funding, weakening long-term self-sufficiency and increasing the likelihood that future strategy depends on dilutive financing or asset sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Rebranding to DataMeds AI and strategic pivot
The rebrand and stated strategy signal a structural shift toward vertically integrated AI and blockchain healthcare data services. By expanding EinsteinRx and PharmacyChain and targeting patient-controlled data, the company aims to build long-term data assets and platform stickiness that can create recurring revenue and differentiation if execution follows plan.
Read all positive factors
Wellgistics Health Inc (WGRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.92M
Dividend YieldN/A
Average Volume (3M)28.82M
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth-51.59%
EPS Growth-25.99%
CountryUS
Employees31
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,647,198
10 Day Avg. Volume1,367,507
30 Day Avg. Volume28,820,997
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap4.82
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit-3.93
Enterprise Value/Ebitda-0.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wellgistics Health Inc Business Overview & Revenue Model
Company Description
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a var...
How the Company Makes Money
null...
Wellgistics Health Inc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.03M | 23.34M | 18.13M | 0.00 | 32.78M |
| Gross Profit | -9.71M | -9.64M | 1.77M | 0.00 | 5.75M |
| EBITDA | -54.45M | -93.48M | -4.91M | -2.88M | -369.03K |
| Net Income | -76.59M | -101.27M | -6.86M | -2.90M | -2.74M |
Balance Sheet | |||||
| Total Assets | 30.13M | 30.46M | 57.33M | 338.36K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 51.73K | 42.57K | 1.03M | 1.36K | 0.00 |
| Total Debt | 28.91M | 24.77M | 25.11M | 700.00K | 0.00 |
| Total Liabilities | 45.19M | 42.91M | 50.60M | 3.24M | 5.25K |
| Stockholders Equity | -15.06M | -12.45M | 6.73M | -2.90M | -5.25K |
Cash Flow | |||||
| Free Cash Flow | -13.11M | -10.86M | -1.60M | -349.14K | 0.00 |
| Operating Cash Flow | -12.92M | -10.86M | -1.22M | -349.14K | 0.00 |
| Investing Cash Flow | -813.49K | -881.53K | 469.07K | 0.00 | 0.00 |
| Financing Cash Flow | 11.27M | 10.75M | 1.78M | 350.50K | 0.00 |
Wellgistics Health Inc Risk Analysis
Wellgistics Health Inc disclosed 64 risk factors in its most recent earnings report. Wellgistics Health Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Wellgistics Health Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $2.50B | 46.51 | 27.21% | ― | 13.54% | ― | |
70 Outperform | $2.38B | 12.75 | 10.29% | ― | -4.31% | -8.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | $7.92M | -0.07 | 1545.09% | ― | -51.59% | -25.99% | |
40 Underperform | $2.62M | -0.11 | 91.30% | ― | -17.53% | -221.57% |
* General Sector Average
WGRX
Wellgistics Health Inc
3.17
-37.36
-92.18%
PBH
Prestige Consumer Healthcare
52.00
-22.04
-29.77%
SNYR
Synergy CHC
0.18
-3.41
-95.11%
GRDN
Guardian Pharmacy Services, Inc. Class A
40.53
19.77
95.23%
Wellgistics Health Inc Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
DataMeds AI rebranding drives healthcare data ecosystem push
Positive
Jul 21, 2026
On July 20, 2026, Wellgistics Health filed a charter amendment in Delaware to change its corporate name to DataMeds AI, Inc., effective July 22, 2026, with no stockholder vote required because the change was limited to the name. The company’...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Wellgistics Regains Nasdaq Bid Compliance Amid Equity Risks
Negative
Jun 12, 2026
Wellgistics Health Inc. disclosed that on April 13, 2026, Nasdaq notified the company that its stockholders’ equity, reported at negative $12.45 million as of December 31, 2025, failed to meet the $2.5 million minimum required for continued ...
Business Operations and StrategyPrivate Placements and Financing
Wellgistics Health Raises Capital Through Convertible Note Financing
Positive
May 29, 2026
On May 27, 2026, Wellgistics Health Inc. entered into a private financing with accredited investors, issuing $21.13 million in convertible notes for $16.91 million in cash proceeds at a 20% discount, alongside long-dated PIPE warrants, with the no...
Business Operations and Strategy
Wellgistics details blockchain-based, AI-driven healthcare infrastructure strategy
Positive
May 21, 2026
On May 21, 2026, Wellgistics Health Inc. issued a shareholder letter outlining how recent strategic transactions are designed to create vertically integrated healthcare infrastructure built on blockchain technology. The company argues that its AI ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceStock Split
Wellgistics Health Announces Transformative AI Healthcare Partnership Deal
Positive
May 21, 2026
On May 20, 2026, Wellgistics Health, Inc. signed a fully binding letter of intent with EOS Technology Holdings, Scilex Holding, Datavault AI, HealthBridge Advisors and Fortitude Advisors for a complex transaction involving QOLPOM/QLPM intellectual...
Business Operations and StrategyFinancial Disclosures
Wellgistics Health Reports Revenue Growth and Narrowed Loss
Positive
May 19, 2026
Wellgistics Health reported first-quarter 2026 results on May 19, 2026, highlighting that revenue rose from $0.486 million in the fourth quarter of 2025 to $0.929 million, while preliminary monthly revenue from its Wellgistics Pharmacy segment inc...
Financial Disclosures
Wellgistics Health Schedules First-Quarter 2026 Earnings Release
Neutral
May 19, 2026
Wellgistics Health, Inc., a healthcare technology and pharmaceutical distribution firm, operates an integrated platform that links thousands of pharmacies with hundreds of drug manufacturers to streamline prescription fulfillment. Its AI-powered E...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Wellgistics Health Withdraws Proxy Amid Strategic Review
Neutral
May 18, 2026
On May 18, 2026, Wellgistics Health, Inc. requested the withdrawal of its Preliminary Proxy Statement on Schedule 14A, which had been filed on May 14, 2026 and related to a special meeting of stockholders. The company chose not to move forward wit...
Business Operations and StrategyPrivate Placements and Financing
Wellgistics Health Enters Forbearance Agreement to Manage Debt
Negative
May 7, 2026
On May 1, 2026, Wellgistics, LLC and its parent Wellgistics Health, Inc. entered into a forbearance and repayment agreement with lender Marco Capital, Inc., formally acknowledging about $1.77 million in outstanding obligations under a November 22,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.